Alicia Rodriguez-Pla, MD
Rheumatology · Fresno, CANPI 1083050025
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $12,625 of the $17,397 with a category attached, or 72.6%. E.r. Squibb & Sons, L.L.C. accounts for 62.0% of it on its own, with 14 other manufacturers making up the rest. 2025 is the largest year on record at $12,396, more than ten times the $162 reported in 2019.
Across 186 payments — averaging $93.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$11K
- AstraZeneca$2K
- AbbVie$1K
- Amgen$800
- Boehringer Ingelheim$675
- Aurinia Pharma U.S., Inc.$442
- plus $1K from 9 others
Across 8 payments — averaging $10,345 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$61K
- Kadmon Corporation LLC$22K
What the payments were for
- Consulting fees$12,62573%
- Food & beverage$4,68127%
- Education$921%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 11 | $10,785 |
| AstraZeneca | 8 | $2,223 |
| AbbVie | 58 | $1,226 |
| Amgen(2 entities) | 56 | $800 |
| Boehringer Ingelheim | 10 | $675 |
| Aurinia Pharma U.S., Inc. | 6 | $442 |
| Johnson & Johnson | 7 | $287 |
| Novartis | 10 | $255 |
| GSK | 6 | $229 |
| Genentech USA, Inc. | 2 | $128 |
| UCB, Inc. | 5 | $123 |
| ANI Pharmaceuticals, Inc. | 4 | $83 |
| Sanofi-aventis U.S. LLC | 1 | $81 |
| Janssen Scientific Affairs, LLC | 1 | $30 |
| Fresenius Kabi USA, LLC | 1 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,397 in reported general payments places this provider in the 80th percentile of 808 rheumatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 20 | $147,997 |
| Hydroxychloroquine Sulfate | 126 | $3,185 |
| Leflunomide | 42 | $1,624 |
| MethotrexateMethotrexate Sodium | 87 | $1,377 |
| Duloxetine Hcl | 82 | $957 |
| Colchicine | 11 | $866 |
| Diclofenac Sodium | 25 | $691 |
| Gabapentin | 77 | $413 |
| Azathioprine | 21 | $322 |
| Prednisone | 65 | $310 |
| Sulfasalazine | 11 | $308 |
| Allopurinol | 16 | $117 |
| Alendronate Sodium | 16 | $107 |
| Meloxicam | 25 | $84 |
| Folic Acid | 17 | $50 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Fresno
- Sudhakar TumuluriSan Francisco$2.8M
- Ara DikranianSan Diego$2.2M
- Orrin TroumSanta Monica$1.8M
- Robin DoreTustin$1.5M
- Samy MetyasCovina$1.3M
- Rhonda LambertSan Mateo$1.1M
- William ShielMission Viejo$924K
- Mark BoriginiDowney$920K
- Adam KreitenbergTarzana$863K
- Roger KornuTustin$802K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.